aTyr Pharma, Inc. (NASDAQ:ATYR) — Market Cap & Net Worth
Market Cap & Net Worth: aTyr Pharma, Inc. (ATYR)
aTyr Pharma, Inc. (NASDAQ:ATYR) has a market capitalization of $36.92 Million ($36.92 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23108 globally and #5054 in its home market, demonstrating a -17.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying aTyr Pharma, Inc.'s stock price $0.38 by its total outstanding shares 98051212 (98.05 Million). Also see balance sheet size of aTyr Pharma, Inc. for a full breakdown of the balance sheet.
aTyr Pharma, Inc. Market Cap History: 2015 to 2026
aTyr Pharma, Inc.'s market capitalization history from 2015 to 2026. Data shows change from $13.49 Billion to $36.92 Million (-42.33% CAGR). Also see aTyr Pharma, Inc. (ATYR) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
aTyr Pharma, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #657 of 976 |
Weight: aTyr Pharma, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
aTyr Pharma, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how aTyr Pharma, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest aTyr Pharma, Inc. stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
404.13x
aTyr Pharma, Inc.'s market cap is 404.13 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $408.87 Million | $422.00K | -$23.60 Million | 968.89x | N/A |
| 2020 | $380.44 Million | $10.46 Million | -$16.22 Million | 36.39x | N/A |
| 2022 | $214.73 Million | $10.39 Million | -$45.34 Million | 20.68x | N/A |
| 2023 | $138.25 Million | $353.00K | -$50.39 Million | 391.65x | N/A |
| 2024 | $354.95 Million | $235.00K | -$64.02 Million | 1510.41x | N/A |
| 2025 | $76.78 Million | $190.00K | -$74.12 Million | 404.13x | N/A |
Competitor Companies of ATYR by Market Capitalization
Companies near aTyr Pharma, Inc. in the global market cap rankings as of September 18, 2026. Review aTyr Pharma, Inc. tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to aTyr Pharma, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
aTyr Pharma, Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, aTyr Pharma, Inc.'s market cap moved from $13.49 Billion to $ 36.92 Million, with a yearly change of -42.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $36.92 Million | -51.92% |
| 2025 | $76.78 Million | -78.37% |
| 2024 | $354.95 Million | +156.74% |
| 2023 | $138.25 Million | -35.62% |
| 2022 | $214.73 Million | -70.68% |
| 2021 | $732.44 Million | +92.53% |
| 2020 | $380.44 Million | -6.95% |
| 2019 | $408.87 Million | -39.95% |
| 2018 | $680.87 Million | -85.83% |
| 2017 | $4.80 Billion | +62.79% |
| 2016 | $2.95 Billion | -78.13% |
| 2015 | $13.49 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of aTyr Pharma, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.92 Million USD |
| MoneyControl | $36.92 Million USD |
| MarketWatch | $36.92 Million USD |
| marketcap.company | $36.92 Million USD |
| Reuters | $36.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinica… Read more